专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

91. 发明申请

US20100120662A1 Glucose uptake modulator and method for treating diabetes or diabetic complications 审中-公开
标题翻译：葡萄糖摄取调节剂和治疗糖尿病或糖尿病并发症的方法
公开(公告)号：US20100120662A1
公开(公告)日：2010-05-13
申请号：US12657083
申请日：2010-01-13
申请人： Kyung-Moo Yea , Jae-Yoon Kim , Jong-Hyun Kim , Byoung-Dae Lee , Seung-Je Lee , Tae-Hoon Lee , Pann-Ghill Suh , Sung-Ho Ryu
发明人： Kyung-Moo Yea , Jae-Yoon Kim , Jong-Hyun Kim , Byoung-Dae Lee , Seung-Je Lee , Tae-Hoon Lee , Pann-Ghill Suh , Sung-Ho Ryu
IPC分类号： A61K38/28 , A61K31/661 , A61K38/16 , A61P3/10
CPC分类号： A61K31/7032 , A61K38/2228 , A61K38/28 , A61K2300/00
摘要： The present invention relates to an glucose uptake modulator, a pharmaceutical composition comprising the glucose uptake modulator, and a method of treating a diabetes or diabetic complications in a mammal in need thereof, which comprises administering to said mammal an effecting amount of a glucose uptake modulator.
摘要翻译：本发明涉及葡萄糖摄取调节剂，包含葡萄糖摄取调节剂的药物组合物和治疗有此需要的哺乳动物的糖尿病或糖尿病并发症的方法，其包括对所述哺乳动物施用有效量的葡萄糖摄取调节剂。

92. 发明申请

US20100113341A1 METHODS OF USING CORTICOTROPIN-RELEASING FACTOR FOR THE TREATMENT OF CANCER 审中-公开
标题翻译：使用CORTICOTROPIN-RELEASING因子治疗癌症的方法
公开(公告)号：US20100113341A1
公开(公告)日：2010-05-06
申请号：US12433652
申请日：2009-04-30
申请人： Stephen Evans-Freke
发明人： Stephen Evans-Freke
IPC分类号： A61K38/16 , A61P35/00
CPC分类号： A61K38/2228 , A61K31/549 , A61K2300/00
摘要： Provided herein is a method for treating cancer in a human by administering a high dose of corticotropin-releasing factor (CRF) for a period of time exceeding 3 days.
摘要翻译：本文提供了通过在超过3天的时间内施用高剂量的促肾上腺皮质激素释放因子（CRF）来治疗人的癌症的方法。

93. 发明申请

US20090291060A1 Treatment of HIV 审中-公开
标题翻译：治疗艾滋病毒
公开(公告)号：US20090291060A1
公开(公告)日：2009-11-26
申请号：US12087442
申请日：2007-01-05
申请人： Deirdre McIntosh
发明人： Deirdre McIntosh
IPC分类号： A61K38/17 , A61K38/20 , A61K38/11 , A61P31/18
CPC分类号： A61K38/2228 , A61K38/16 , A61K38/1709 , A61K38/1774 , A61K38/1841 , A61K38/2066 , A61K38/22 , A61K38/33 , A61K38/34 , A61K38/35 , A61K2300/00
摘要： We describe methods of treatment of HIV using proopiomelanocortin (POMC) and corticotropin releasing factor (CRF) peptides and their products, as well as uses of such peptides in the preparation of medicaments.
摘要翻译：我们描述了使用促皮质素皮质素（POMC）和促肾上腺皮质激素释放因子（CRF）肽及其产物治疗HIV的方法，以及这些肽在制备药物中的用途。

94. 发明申请

US20080207500A1 Medicament 审中-公开
标题翻译：药物
公开(公告)号：US20080207500A1
公开(公告)日：2008-08-28
申请号：US11631067
申请日：2005-07-08
申请人： Deirdre McIntosh
发明人： Deirdre McIntosh
IPC分类号： A61K38/22 , C07K14/575 , C07K1/00 , A61P25/00
CPC分类号： A61K38/2228 , A61K38/095 , A61K38/22 , A61K38/33 , A61K38/34 , Y02A50/463 , A61K2300/00
摘要： Analysis of a goat serum product with many therapeutic effects is described. The product is identified as containing proopiomelanocortin (POMC) and Corticotropin releasing factor (CRF) peptides, as well as breakdown products of these peptides. We describe methods of treatment of diseases including cancers, multiple sclerosis, and neural disorders using these peptides and their products, as well as medicaments including such peptides and methods of producing the peptides.
摘要翻译：描述了具有许多治疗效果的山羊血清产物的分析。该产物被鉴定为含有促皮质素皮质素（POMC）和促皮质激素释放因子（CRF）肽，以及这些肽的分解产物。我们描述了使用这些肽及其产物的包括癌症，多发性硬化和神经障碍在内的疾病的治疗方法，以及包括这些肽的药物和生产肽的方法。

95. 发明授权

US07034118B2 Corticotropin-releasing factor2 receptors 失效
标题翻译：促肾上腺皮质激素释放因子2受体
公开(公告)号：US07034118B2
公开(公告)日：2006-04-25
申请号：US10821502
申请日：2004-04-09
申请人： Timothy W Lovenberg , Tilman Oltersdorf , Chen Wang Liaw , Dimitri E Grigoriadis , Derek T Chalmers , Errol B DeSouza
发明人： Timothy W Lovenberg , Tilman Oltersdorf , Chen Wang Liaw , Dimitri E Grigoriadis , Derek T Chalmers , Errol B DeSouza
IPC分类号： C07K14/705
CPC分类号： C07K14/72 , A61K38/2228
摘要： The present invention provides isolated nucleic acid molecules encoding CRF2 receptors, recombinant expression vectors and host cells suitable for expressing such receptors, as well as compositions and methods which utilize such receptors.
摘要翻译：本发明提供编码CRF 2受体的分离的核酸分子，适用于表达这种受体的重组表达载体和宿主细胞，以及利用这种受体的组合物和方法。

96. 发明申请

US20040185533A1 Corticotropin-releasing factor2 receptors 失效
公开(公告)号：US20040185533A1
公开(公告)日：2004-09-23
申请号：US10821502
申请日：2004-04-09
申请人： Neurocrine Biosciences, Inc.
发明人： Timothy W. Lovenberg , Tilman Oltersdorf , Chen Wang Liaw , Dimitri E. Grigoriadis , Derek T. Chalmers , Errol B. DeSouza
IPC分类号： C07K014/705 , C07K016/28 , C07H021/04
CPC分类号： C07K14/72 , A61K38/2228
摘要： The present invention provides isolated nucleic acid molecules encoding CRF2 receptors, recombinant expression vectors and host cells suitable for expressing such receptors, as well as compositions and methods which utilize such receptors.

97. 发明申请

US20020077468A1 Corticotropin-releasing factor2 receptors 失效
标题翻译：促肾上腺皮质激素释放因子2受体
公开(公告)号：US20020077468A1
公开(公告)日：2002-06-20
申请号：US09881401
申请日：2001-06-13
发明人： Timothy W. Lovenberg , Tilman Oltersdorf , Chen Wang Liaw , Dimitri E. Grigoriadis , Derek T. Chalmers , Errol B. DeSouza
IPC分类号： C07H021/04 , C12P021/02 , C07K014/705 , C12N005/06
CPC分类号： C07K14/72 , A61K38/2228
摘要： The present invention provides isolated nucleic acid molecules encoding CRF2 receptors, recombinant expression vectors and host cells suitable for expressing such receptors, as well as compositions and methods which utilize such receptors.
摘要翻译：本发明提供编码CRF2受体的分离的核酸分子，适用于表达这种受体的重组表达载体和宿主细胞，以及利用这种受体的组合物和方法。

98. 发明授权

US5306710A Method for treating endotoxin shock with CRF 失效
标题翻译：用CRF治疗内毒素休克的方法
公开(公告)号：US5306710A
公开(公告)日：1994-04-26
申请号：US876487
申请日：1992-04-30
申请人： Edward T. Wei
发明人： Edward T. Wei
IPC分类号： A01D1/02 , A01N1/02 , A61K38/22 , A61P3/00 , C07K14/575 , A61K37/40
CPC分类号： A61K38/2228 , A01N1/021 , A01N1/0226
摘要： Administration of a Corticotropin-Releasing Factor (or a salt or analog thereof) decreases the leakage of blood components into brain tissue produced by various adverse medical conditions and reduces bleeding when muscle tissues are cut and handled, such as in plastic and reconstructive surgery. A method of treating a patient for injury to or disease of the brain, central nervous system, or musculature in which edema is a factor comprises administering to the patient a Corticotropin-Releasing Factor (or a salt or analog) in an amount effective to decrease vascular permeability in the injured or diseased brain, nervous system tissue or musculature, and thereby to reduce edema. Administration in accordance with the method can be about two hours before surgery, or can be up to three days after injury.
摘要翻译：促肾上腺皮质激素释放因子（或其盐或类似物）的施用减少了由各种不利的医学条件产生的血液成分渗透到脑组织中，并且在肌肉组织被切割和处理时减少出血，例如在塑性和重建手术中。治疗患者对水肿是水肿的脑，中枢神经系统或肌肉组织的损伤或疾病的方法包括向患者施用有效降低的量的促肾上腺皮质激素释放因子（或盐或类似物）损伤或患病的脑，神经系统组织或肌肉组织中的血管通透性，从而减少水肿。按照方法管理可以在手术前约两个小时，否则可能在伤后三天内。

99. 发明授权

US5209920A Evaluative means for detecting inflammatory reactivity 失效
标题翻译：用于检测炎症反应性的评估手段
公开(公告)号：US5209920A
公开(公告)日：1993-05-11
申请号：US412294
申请日：1989-09-25
申请人： Esther M. Sternberg , Ronald L. Wilder , Philip W. Gold , George P. Chrousos
发明人： Esther M. Sternberg , Ronald L. Wilder , Philip W. Gold , George P. Chrousos
IPC分类号： A61K31/135 , A61K31/35 , A61K31/365 , A61K31/40 , A61K31/485 , A61K31/495 , A61K31/565 , A61K31/57 , A61K31/585 , A61K38/22 , A61K45/06 , G01N33/50 , G01N33/564 , G01N33/74
CPC分类号： A61K31/135 , A61K31/35 , A61K31/365 , A61K31/40 , A61K31/485 , A61K31/495 , A61K31/565 , A61K31/57 , A61K31/585 , A61K38/11 , A61K38/2228 , A61K45/06 , G01N33/5091 , G01N33/564 , G01N33/74 , G01N33/743 , G01N2800/102 , Y10S435/975 , Y10S514/805 , Y10S514/825 , Y10S514/885 , Y10S514/886 , Y10S514/889
摘要： Inbred Lewis (LEW/N) female rats develop an arthritis in response to Group A streptococcal cell wall peptidoglycanpolysaccharide (SCW) which mimics human rheumatoid arthritis. Histocompatible Fischer (F344/N) rats, on the other hand, do not develop arthritis in response to the same SCW stimulus. To evaluate this difference in inflammatory reactivity between the two strains, the function of the hypothalamic-pituitary-adrenal axis and its ability to modulate the development of the inflammatory response was studied. It has been found that, in contrast to F344/N rats, LEW/N rats had markedly impaired plasma ACTH and corticosterone responses to SCW, recombinant human Interleukin-1 alpha (IL-1 alpha), the serotonin agonist, quipazine, and synthetic rat corticotropin-releasing hormone (CRH). In addition, LEW/N rats compared to F344/N rats had smaller adrenal glands and larger thymuses. Treatment of LEW/N rats with replacement doses of dexamethasone decreased the severity of their SCW-induced arthritis. Conversely, treatment of F344/N rats with the glucocorticoid receptor antagonist, RU 486, or the serotonin (5-HT.sub.2) antagonist, LY53857, was associated with development of severe inflammatory disease, including arthritis, in response to SCW. These findings support the concept that susceptibility of LEW/N rats to SCW arthritis is related to abnormal hypothalamic-pituitary-adrenal (HPA) axis responsiveness to inflammatory and other stress mediators and that resistance of F344/N rats to SCW arthritis is regulated by an intact HPA axis-immune system feedback loop.
摘要翻译：近交路易斯（LEW / N）雌性大鼠针对模拟人类类风湿关节炎的A组链球菌细胞壁肽聚糖多糖（SCW）产生关节炎。另一方面，组织相容性Fischer（F344 / N）大鼠不会对相同的SCW刺激产生关节炎。为了评估两种菌株之间的炎症反应性差异，研究了下丘脑 - 垂体 - 肾上腺轴的功能及其调节炎症反应发展的能力。已经发现，与F344 / N大鼠相比，LEW / N大鼠对SCW，重组人白细胞介素-1α（IL-1α），血清素激动剂，喹地平和合成的血浆ACTH和皮质酮反应明显受损大鼠促肾上腺皮质激素释放激素（CRH）。此外，与F344 / N大鼠相比，LEW / N大鼠具有较小的肾上腺和较大的胸腺。用替代剂量的地塞米松治疗LEW / N大鼠降低其SCW诱导的关节炎的严重程度。相反，用糖皮质激素受体拮抗剂RU 486或5-羟色胺（5-HT2）拮抗剂LY53857处理F344 / N大鼠与SCW相关的严重炎症性疾病（包括关节炎）的发展有关。这些发现支持LEW / N大鼠对SCW关节炎的易感性与异常的下丘脑 - 垂体 - 肾上腺（HPA）轴对炎症和其他应激介质的反应性有关的概念，F344 / N大鼠对SCW关节炎的抵抗力由完整的HPA轴免疫系统反馈回路。

100. 发明申请

WO2019140030A1 COMBINATION THERAPY 审中-公开
公开(公告)号：WO2019140030A1
公开(公告)日：2019-07-18
申请号：PCT/US2019/012963
申请日：2019-01-10
申请人： ELI LILLY AND COMPANY
发明人： ALSINA-FERNANDEZ, Jorge , COSKUN, Tamer
IPC分类号： A61K38/26 , A61K38/22 , A61P3/10
CPC分类号： A61K38/2228 , A61K38/26 , A61P3/10 , A61K2300/00
摘要： The disclosure describes a combination therapy for treating diabetes or chronic kidney disease by administering to a patient in need of such treatment an effective amount of a urocortin-2 compound (or a pharmaceutically acceptable salt thereof) with a GIP/GLP-1 co-agonist analog (or a pharmaceutically acceptable salt thereof), and to methods of using the same to treat diabetes and chronic kidney disease.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式